ValuEngine Lowers Calithera Biosciences (CALA) to Sell

Calithera Biosciences (NASDAQ:CALA) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

A number of other analysts have also weighed in on the company. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Monday, November 6th. William Blair started coverage on Calithera Biosciences in a research note on Thursday, October 5th. They issued an “outperform” rating on the stock. Finally, BidaskClub upgraded Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $15.17.

Calithera Biosciences (CALA) traded down $0.15 during trading hours on Friday, reaching $10.35. The company had a trading volume of 490,579 shares, compared to its average volume of 1,015,732. Calithera Biosciences has a one year low of $2.90 and a one year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.02 million. equities analysts forecast that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 16.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. California Public Employees Retirement System increased its stake in shares of Calithera Biosciences by 210.1% during the third quarter. California Public Employees Retirement System now owns 43,719 shares of the biotechnology company’s stock valued at $689,000 after buying an additional 29,619 shares during the period. Wells Fargo & Company MN increased its stake in shares of Calithera Biosciences by 25.8% during the third quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 6,910 shares during the period. Trexquant Investment LP purchased a new position in shares of Calithera Biosciences during the third quarter valued at $168,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Calithera Biosciences by 48.4% during the third quarter. Dynamic Technology Lab Private Ltd now owns 34,845 shares of the biotechnology company’s stock valued at $549,000 after buying an additional 11,368 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Calithera Biosciences by 272.8% during the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock valued at $6,690,000 after buying an additional 310,806 shares during the period. Hedge funds and other institutional investors own 72.33% of the company’s stock.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/03/valuengine-lowers-calithera-biosciences-cala-to-sell.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply